PledPharma

Interim report January-June 2017

CONTENTS

SUMMARY 1
COMMENTS FROM THE CEO 2
PROJECT UPDATE 3
PLEDOX® 3
ALADOTE® 4
FINANCIAL INFORMATION 5
OTHER INFORMATION 14

SUMMARY

Q2 IN BRIEF

- Nicklas Westerholm was recruited as the new CEO for PledPharma
- PledPharma received advice from the FDA for the continued development of PledOx® and is now following up with the EMA
- Christian Sonesson was recruited as Vice President Product Strategy and Development
- Marie Ekström Trägårdh was elected to the board of directors

SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD

- PledPharma established a scientific advisory board for the PledOx® program
- PledPharma recruited Stefan Carlsson as new Chief Medical Officer
- 8 out of 24 patients completed their treatment in the Proof of principle study with Aladote®

FINANCIALS

- Quarterly result MSEK -16,2 (-12,0)
- Cash MSEK 363,7 (31,7)
- Cash flow from operating activities MSEK -19,6 (-12,0)
- Result per share SEK -0,3 (-0,4)
- A warrants program was established

FIRST HALF YEAR IN BRIEF

- Gunilla Osswald and Elisabeth Svanberg were elected to the Board of Directors.
- PledPharma's key patent application for the active pharmaceutical ingredient of the drug candidates PledOx® and Aladote® was approved in Japan and Russia.
- Patent for the anticancer-effect of PLED compounds was approved in Canada and an important use patent for PLED compounds was approved in Israel.

FINANCIALS

- Result for the period MSEK -28,5 (-18,8)
- Cash MSEK 363,7 (31,7)
- Cash flow from operating activities MSEK -31,6 (-18,7)
- Result per share SEK-0,6 (-0,7)

FINANCIAL SUMMARY

	2017 April- June	2016 April- June	2017 Jan-June	2016 Jan-June	2016 Jan-Dec
Result after tax, KSEK	-16 189	-11 984	-28 470	-18 829	-38 223
Cash flow, KSEK	-18 293	-12 018	-30 251	-18 695	343 638
Cash, KSEK	363 748	31 666	363 748	31 666	393 998
Equity ratio %	98%	71%	98%	71%	98%
Result per share, SEK	-0,3	-0,4	-0,6	-0,7	-1,3
Result per share after dilution, SEK	-0,3	-0,4	-0,6	-0,7	-1,3
Number of employees	5	4	5	4	4

COMMENTS FROM THE CEO

It is with great pleasure and enthusiasm I have assumed the role as CEO of PledPharma after about 20 years within the Astra and AstraZeneca Group, where I developed my knowledge and gained experience in global drug development, production issues, development cooperation and investor relations of global drug development, production issues, development cooperation and investor relations. Of course, there is much that is different between AstraZeneca and PledPharma, but there are also challenges common to both companies. Not least, the pursuit of professionally and efficiently developing new drugs that meet unmet medical needs which creates significant value for the company's Investors. Likewise, the need to ensure a well-functioning organization with the skills and resources required to achieve set goals.

Since joining in June, my colleagues and I have focused our work in three areas:

Strengthen the organization and capabilities
We have started an intensive work to strengthen PledPharmas organization and capabilities for the continued clinical development of our two pharmaceutical projects PledOx® and Aladote®. This has already resulted in the recruitment of two new key individuals. Dr Stefan Carlsson, in his role as Chief Medical Officer, he will have overall responsibility for the continued clinical development of our two drug candidates. Our new Vice President Product Strategy & Development, Dr. Christian Sonesson, who will lead the remaining PledOx® development program and be responsible for the design of pricing strategies, initial market positioning and potential future indications. Both Stefan and Christian have solid experience and knowledge within their areas of responsibility.

Optimize the development programs
Optimized program for PledOx®
The most central task is to optimize the design of the remaining clinical development program for PledOx® in terms of cost aspects, time efficiency and quality. An important complement in this process is our newly established scientific advisory board, consisting of five internationally leading experts in oncology, neurology, chronic pain management and methods for measuring patients' reported outcomes in clinical trials.

After receiving advice from FDA for forthcoming clinical studies with PledOx® we are now following up with the European Medicines Agency (EMA).

Progress in the Aladote program
At the end of the quarter, we started our proof of principle study with Aladote® and we are pleased to announce that one third of the patients have already undergone treatment. This is the first time that Aladote® is tested in patients who overdose paracetamol.

Increased transparency to the financial market
The third of my initial focus areas is to ensure high transparency and good dialogue with the financial market. I have already had the opportunity to meet several of our major shareholders and look forward to expanding my interactions with both current shareholders and potential new investors in the autumn to describe how we work to build commercial values in the company.

It is a combination of professional scientific work, clinical development work, thought-through regulatory strategies, and - not least - business acumen that provides the cornerstones for value growth in a company of PledPharma's character. I will do my utmost to ensure that the company optimizes its work in all of these areas.

Nicklas Westerholm
CEO

PLEDPHARMA IN BRIEF

PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose.

The company's most advanced project **PledOx®** is being developed to reduce nerve damage associated with chemotherapy. A phase IIb study has been conducted and will serve as the basis for the continued development.

The drug candidate **Aladote®** is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning.

PledPharma (STO:PLED) is listed on Nasdaq First North.

For further information, please contact:
Nicklas Westerholm, VD
Phone: +46 73-354 20 62
e-mail: nicklas.westerholm@pledpharma.se

PledPharma AB (publ)
Grev Turegatan 11c, 114 46 Stockholm
Phone: +46 8-679 72 10
www.pledpharma.se

PROJECT UPDATES

PLEDOX®

PLEDOX® IN BREIF

PledOx® is developed to provide patients, that are treated adjuvantly or for metastatic colorectal cancer, protection against the nerve damage that can occur in conjunction with chemotherapy treatment. The side-effects of chemotherapy can lead to a reduction of the planned dose or in worst case, treatment discontinuation. Unfortunately, it appears that the chemotherapy can induce permanent nerve damage. Patients may, for example, experience discomfort and numbness in the hands and feet, difficulty with balance with risk of falling and problems with sensation that can last for the rest of their lives.

The results from the Phase IIb study PLIANT, where patients with metastatic colorectal cancer were treated with the chemotherapy combination FOLFOX and PledOx® (calmangafodipir), indicates that the patients who received PledOx® had a lower risk than the placebo group to suffer from nerve damage during the chemotherapy.

The presence of the investigator reported sensory nerve damage, the primary endpoint, was after treatment 43 percent lower in the group of patients treated with PledOx® compared with the placebo group ($p = 0.14$). This was not statistically significant, but a difference of this magnitude is considered to be clinically relevant. No apparent negative effect on the efficacy of the cancer treatment was observed. Furthermore, there was a coherence between investigator reported sensory nerve damage and the different patient reported evaluations made, which is valuable for future studies.

Post hoc analyzes on patient-reported neuropathy show a statistically significant reduction in the incidence and intensity of the symptoms of nerve damage in comparison with placebo. Additionally, it was noted that the investigator-reported symptoms of neuropathy occur later and disappear faster after pretreatment with PledOx®.

During the follow-up after completion of chemotherapy, the patient-reported incidence and intensity of neuropathy was statistically significantly lower in patients pretreated with PledOx®. The severity of neuropathy was 62 percent lower 12 weeks after discontinuation of treatment in the group of patients

treated with PledOx® versus placebo (p <0.05) and at 24 weeks the corresponding difference between PledOx® and placebo group was 75 percent (p <0, 01).

PledPharma is preparing to initiate the remaining clinical trials with PledOx® in 2017.

EVENTS DURING Q2

In the second quarter, intensive work has been ongoing to prepare for the start of the upcoming clinical trials with PledOx®. During the quarter, PledPharma has sought follow-up scientific and regulatory advice by the European Medicines Agency (EMA) for the up-coming clinical trials.

Recruitments have been made to strengthen the project and the Christian Sonesson has joined as Vice President Product Strategy and Development and Stefan Carlsson will join as the new Chief Medical Officer on November 1.

In August, a scientific advisory board (SAB) was established for the continued clinical development of PledOx® in order to give PledPharma valuable views and input on the design of the remaining clinical trial program and the regulatory strategy for PledOx®, aiming at maximizing the potential for market approval and optimizing the commercial potential of the drug candidate. The SAB will consist of the following internationally leading experts in oncology (Professor Emeritus Bengt Glimelius, Sweden), Neurology (Professor Guido Cavaletti, Italy), Chronic Pain (Professor Rolf Karlsten, Sweden) and Methods for Measuring Patients' Quality of Life (Professor David Cella, USA) and a non-named leading international expert from the United States in the field of chemotherapy induced peripheral neuropathy.

ALADOTE®

ALADOTE® IN BREIF

Aladote® is being developed to counter the onset of acute liver failure caused by paracetamol (acetaminophen) poisoning. Paracetamol is one of the most commonly used drugs in both deliberate and accidental overdoses. High concentrations of paracetamol breaking down in the liver can lead to acute liver failure, and even death. The current treatment for paracetamol poisoning (N-acetylcysteine) is effective if the patient seeks medical care within 8 hours of ingestion. However, there is currently no well-functioning treatment for patients who arrive more than 8 hours after ingestion.

Preclinical studies have shown that Aladote® was effective in animal models for a much longer period than N-acetylcysteine (NAC). Aladote® is a "first-in-class" treatment and there is a large medical need as there are currently no adequate treatment for patients that arrive late to the hospital after an overdose of aciteminophen. An Aladote® safety and tolerability study has begun at the Edinburgh Royal Infirmary. This is the first time that Aladote® is tested in patients who overdose paracetamol. The trial is being led by Dr James Dear, Reader in Pharmacology at the University of Edinburgh.

EVENTS DURING Q2

During the quarter, the proof of principle study in patients with paracetamol poisoning has started at the Edinburgh Royal Infirmary and the first patient was included in June. After the end of the quarter, 8 patients out of a total of 24 patients have completed their treatment in the study in which safety and tolerability are tested.

FINANCIAL INFORMATION

REVENUE, EXPENSES AND RESULTS

Revenues

Revenue amounted to KSEK 144 (897) during the quarter and to KSEK 201 (945) for the half year. The revenue consisted of foreign exchange gains. The difference between the periods 2016 and 2017 is explained by a retroactive price adjustment of KSEK 839 in the PLIANT study during the second quarter of 2016. Interest income amounted to KSEK 36 (37) for the quarter and to KSEK 81 (75) for the half year.

Expenses

Operating expenses amounted to KSEK 16 369 (12 918) for the quarter and to KSEK 28 751 (19 849) for the half year. Of these, planned project costs amounted to KSEK 10 684 (7 511) for the quarter and to KSEK 17 731 (9 425) for the half year. The increase of costs during the quarter was associated with the manufacturing of PledOx for the continued clinical development and cost related to safety studies.

Employee costs amounted to KSEK 2 143 (1 597) for the quarter and to KSEK 3 999 (3 187) for the half year period. Other operating costs amounted to KSEK 3 466 (3 570) for the quarter and to KSEK 6 907 (6 983) for the half year and included costs of license patents and consulting costs. Depreciation amounted to KSEK 0 (0) for the periods.

Results

Operating result amounted to KSEK -16 225 (-12 021) for the quarter and to KSEK -28 550 (-18 904) for the half year. Result after financial items amounted to KSEK -16 189 (-11 984) for the quarter and to KSEK -28 470 (-18 829) for the half year. No income tax was reported for the periods (-). Result per average share before and after dilution amounted to SEK -0.3 (-0.4) for the quarter and to SEK -0,6 (-0,7) for the half year.

FINANCIAL POSITION

Cash

Cash at June 30 2017 amounted to KSEK 363 748 (31 666).

Cash flow

Cash flow from operating activities amounted to KSEK -19 617 (-12 018) for the quarter and to -31 575 (-18 695) for the half year. The cash flow from investment activites amounted to KSEK 0 (0). Cash flow from financial activities amounted to KSEK 1 324 (0) and relates to the issue of warrants for the employees. Cash flow amounted to KSEK -18 293 (-12 018) for the quarter and to KSEK -30 251 (-18 695) for the half year.

Equity and equity ratio

At June 30, 2017 equity amounted to KSEK 362 417 (29 203). Shareholders' equity per share amounted to SEK 7.6 (1.0), at the end of the period. The company's equity ratio was 98 (71) %.

Debts

No long-term debts were outstanding (-). Current liabilities amounted to KSEK 5 586 (12 020).

INVESTMENTS, TANGIBLE AND INTANGIBLE ASSETS

During the period, investments in tangible fixed assets corresponding to KSEK 0 (0).

SHARE

The number of shares at June 30, 2017 were 48 666 656. PledPharma´s shares were listed on NASDAQ Stockholm First North on 7 April 2011.

WARRANT PROGRAM

The Annual General Meeting 2017 resolved on an warrants program for employees and board members of PledPharma of 2,306,000 warrants, each warrants entitling the holder to subscribe for one (1) new share in the company at a subscription price of SEK 26 per share. At full utilization of all options, the company's shares will be increased by 2,306,000 to 50,972,656. As of June 30, 2017, 1,026,500 warrants had been subscribed for by employees and board members of PledPharma.

EMPLOYEES

Number of employees as of June 30, 2017 was 5 (4) persons, 3 women and 2 men.

PARENT COMPANY

The parent company's expenses for the quarter amounted to KSEK 16 369 (12 918) and to KSEK 28 751 (19 849) for the half year.
The parent company's result after financial items amounted to KSEK -16 189 (-11 984) for the quarter and to KSEK -28 470 (-18 829) for the half year.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

SEKk	2017 April-June	2016 April - June	2017 Jan-June	2016 Jan - June	2016 Jan - Dec
Revenue					
Other operating income	144	897	201	945	1 026
	144	**897**	**201**	**945**	**1 026**
Operating expenses					
Project costs	-10 684	-7 511	-17 731	-9 425	-19 513
Other external costs	-3 466	-3 570	-6 907	-6 983	-13 162
Employee benefit costs	-2 143	-1 597	-3 999	-3 187	-6 357
Depreciation and impairment, fixed assets	0	0	0	0	0
Other operating expenses	-75	-239	-114	-253	-356
Operating result	**-16 225**	**-12 021**	**-28 550**	**-18 904**	**-38 363**
Net financial items					
Interest income	36	37	81	75	140
Interest expense and similar items	-	-	-	-	-
Result after financial net	**-16 189**	**-11 984**	**-28 470**	**-18 829**	**-38 223**
Result before tax	**-16 189**	**-11 984**	**-28 470**	**-18 829**	**-38 223**
Tax	-	-	-	-	-
Result after tax	**-16 189**	**-11 984**	**-28 470**	**-18 829**	**-38 223**
Statement of comprehensive income					
Other comprehensive income	-	-	-	-	-
Comprehensive income for the period	**-16 189**	**-11 984**	**-28 470**	**-18 829**	**-38 223**
Net earnings and comprehensive income is entirely attributable to parent company shareholders					
Share Data					
Number of shares at the end of period	48 666 656	28 388 883	48 666 656	28 388 883	48 666 656
Average number of shares during period	48 666 656	28 388 883	48 666 656	28 388 883	29 675 504
Result per share before dilution (SEK)	-0,3	-0,4	-0,6	-0,7	-1,3
Result per share after dilution (SEK)	-0,3	-0,4	-0,6	-0,7	-1,3
Equity per share (SEK)	7,6	1,0	7,6	1,0	8,0
Equity per share after dilution (SEK)	7,1	1,0	7,1	1,0	8,0

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

SEKk	2017-06-30	2016-06-30	2016-12-31
ASSETS			
Fixed assets			
Property, plant and equipment			
Equipment, tools, fixtures and fittings	0	0	0
Total fixed assets	0	0	0
Current assets			
Current receivables			
Other receivables	713	6 589	1 344
Prepaid expenses and accrued income	3 542	2 969	1 093
	4 255	9 558	2 437
Cash and bank balances	363 748	31 666	393 998
Total current assets	**368 003**	**41 224**	**396 435**
Total assets	**368 003**	**41 224**	**396 435**
EQUITY AND LIABILITIES			
Equity			
Share capital	2 561	1 494	2 561
Other capital contributions	388 325	46 538	425 224
Accumulated loss including net loss	-28 470	-18 829	-38 223
Total equity	**362 417**	**29 203**	**389 562**
Short term liabilities			
Accounts payable	3 538	9 449	4 678
Tax liabilities	-	-	-
Other liabilities	286	196	213
Accrued expenses and deferred income	1 762	2 375	1 983
Total short term liabilities	**5 586**	**12 020**	**6 873**
Total equity and liabilities	**368 003**	**41 224**	**396 435**

CONSOLIDATED STATEMENT OF CASH FLOWS

SEKk	2017 April -June	2016 April - June	2017 Jan - June	2016 Jan - June	2016 Jan-Dec
OPERATING ACTIVITIES					
Result after financial net	-16 189	-11 984	-28 470	-18 829	-38 223
Adjustments for non-cash items	0	0	0	0	0
Tax paid	0	0	0	0	0
Cash flow from operating activities before changes in working capital	**-16 189**	**-11 984**	**-28 470**	**-18 829**	**-38 223**
Changes in short term liabilities	323	-8 574	-1 818	-7 557	-436
Changes in account payables	-2 485	8 347	-1 140	7 683	2 912
Changes in operating liabilities	-1 266	193	-147	9	-367
Cash flow from operating activities	**-19 617**	**-12 018**	**-31 575**	**-18 695**	**-36 114**
INVESTING ACTIVITIES					
Cash flow from investing activities	**-**	**-**	**-**	**-**	**-**
FINANCING ACTIVITIES					
New share issue/warrants issue	1 324	-	1 324	-	405 555
Cost new share issue	-	-	-	-	-25 803
Cash flow from financing activities	**1 324**	**-**	**1 324**	**-**	**379 753**
Cash flow for the period					
Balance at beginning of period	382 041	43 684	393 998	50 360	50 360
Change in cash	-18 293	-12 018	-30 251	-18 695	343 638
CASH BALANCE AT THE END OF THE PERIOD	363 748	31 666	363 748	31 666	393 998

CONSOLIDATES STATEMENT OF CHANGES IN EQUITY

kSEK	Share capital	Other capital contributions	Accumulated loss incl. net result for the period	Totalt equity
Opening balance 20160101	**1 494**	**90 374**	**(43 836)**	**48 032**
Loss allocation according to AGM	-	(43 836)	43 836	-
Comprehensive income for period	-	-	(18 829)	(18 829)
Closing balance 20160630	**1 494**	**46 538**	**(18 829)**	**29 203**
Opening balance 20170101	**2 561**	**425 224**	**(38 223)**	**389 562**
Loss allocation according to AGM	-	(38 223)	38 223	-
Issue of warrants	-	1 325	-	-
Comprehensive income for period	-	-	(28 470)	(28 470)
Closing balance 20170630	**2 561**	**388 325**	**(28 470)**	**362 417**
Opening balance 20160101	**1 494**	**90 374**	**(43 836)**	**48 032**
Loss allocation according to AGM	-	(43 836)	43 836	-
New share issue	1 067	404 488	-	405 555
Costs new share issue	-	(25 803)	-	(25 803)
Comprehensive income for period	-	-	(38 223)	(38 223)
Closing balance 20161231	**2 561**	**425 224**	**(38 223)**	**389 562**

CONSOLIDATED KEY RATIOS

The key ratios below are useful to those who read the financial statements and a complement to other performance targets in evaluating strategic investment implementation and the Group's ability to achieve financial goals and commitments.

KSEK	2017 April - June	2016 April - June	2017 Jan-June	2016 Jan - June	2016 Jan - Dec
Equity	362 417	29 203	362 417	29 203	389 562
Equity ratio %	98%	71%	98%	71%	98%
Return on equity %	neg.	neg.	neg.	neg.	neg.
Number of shares at the end of the period	48 666 656	28 388 883	48 666 656	28 388 883	48 666 656
Number of shares at the end of the period after dilution	50 972 656	28 388 883	50 972 656	28 388 883	48 666 656
Average number of shares under the period	48 666 656	28 388 883	48 666 656	28 388 883	29 675 504
Average number of shares under the period after dilution	50 972 656	28 388 883	50 972 656	28 388 883	29 675 504
Share Data					
Result per share	-0,3	-0,4	-0,6	-0,7	-1,3
Result per share after dilution*	-0,3	-0,4	-0,6	-0,7	-1,3
Cash flow from operating activities	-0,4	-0,4	-0,6	-0,7	-1,2
Equity per share	7,6	1,0	7,6	1,0	8,0
Equity per share after dilution	7,1	1,0	7,1	1,0	8,0
Dividend	-	-	-	-	-
Number of employees	5	4	5	4	4

*Effect from dilution is not considered when result is negative.

KEY RATIOS DEFINITIONS

Ratios that have been calculated according to IFRS

Earnings per share
Net income divided by average number of shares before dilution
Number of shares at end of period
The number of outstanding shares before dilution at the end of the period
Number of shares after dilution
The number of issued shares after dilution effect of potential shares at end of period
Average number of shares during the period
Average number of outstanding shares before dilution for the period
Average number of shares during the period after dilution
Average number of issued shares after dilution effect of potential shares
Number of employees (average)
The average number of employees at the end of each period

Ratios that have not been calculated in accordance with IFRS

Equity ratio, %
The company defines the ratio as follows; The period's closing equity divided by the period's closing balance sheet. The company uses the alternate ratio Equity as it shows the proportion of total assets represented by shareholders' equity and has been included to allow investors to assess the company's capital structure.

Return on equity, %
The company defines the ratio as follows; Net income divided by shareholders' equity. The company uses the alternate key figure Return on equity, % because the company believes that the key ratio gives investors a better understanding of the return generated on the total capital that the shareholders have invested in the Company.

Cash flow from operations per share
The company defines the ratio as follows; Cash flow from operating activities divided by the number of shares outstanding at the end of the period. The company uses the alternate key figure Cash flow from operations per share because the Company believes that the key ratio gives investors a better understanding of the company's cash flow in relation to its number of shares adjusted for changes in the number of shares outstanding during the period.

Equity per share
The company defines the ratio as follows; Equity divided by number of shares outstanding at the end of the period. The company uses the alternate key ratio equity per share because the Company believes that the key ratio gives investors a better understanding of the historical return per share adjusted for changes in the number of shares outstanding during the period.

PARENT COMPANY - INCOME STATEMENT

SEKk	2017 April-June	2016 April - June	2017 Jan-June	2016 Jan - June	2016 Jan - Dec
Revenue					
Other operating income	144	897	201	945	1 026
	144	**897**	**201**	**945**	**1 026**
Operating expenses					
Project costs	-10 684	-7 511	-17 731	-9 425	-19 513
Other external costs	-3 466	-3 570	-6 907	-6 983	-13 162
Employee benefit costs	-2 143	-1 597	-3 999	-3 187	-6 357
Depreciation and impairment, fixed assets	0	0	0	0	0
Other operating expenses	-75	-239	-114	-253	-356
Operating result	**-16 225**	**-12 021**	**-28 550**	**-18 904**	**-38 363**
Net financial items					
Interest income	36	37	81	75	140
Interest expense and similar items	-	-	-	-	-
Result after financial net	**-16 189**	**-11 984**	**-28 470**	**-18 829**	**-38 223**
Result before tax	**-16 189**	**-11 984**	**-28 470**	**-18 829**	**-38 223**
Tax	-	-	-	-	-
Result after tax	**-16 189**	**-11 984**	**-28 470**	**-18 829**	**-38 223**

PARENT COMPANY - BALANCE SHEET

SEKk	2017-06-30	2016-06-30	2016-12-31
ASSETS			
Fixed assets			
Property, plant and equipment			
Equipment, tools, fixtures and fittings	0	0	0
Financial assets			
Shares and participations in group companies	50	50	50
Total fixed assets	**50**	**50**	**50**
Current assets			
Current receivables			
Other receivables	713	6 589	1 344
Prepaid expenses and accrued income	3 542	2 969	1 093
	4 255	9 558	2 437
Cash and bank balances	362 424	31 666	393 998
Total current assets	**366 678**	**41 224**	**396 435**
Total assets	**366 728**	**41 274**	**396 485**
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share capital	2 561	1 494	2 561
Non-restricted equity			
Share premium reserve	387 000	46 538	425 224
Result for the period	-28 470	-18 829	-38 223
Total equity	**361 092**	**29 203**	**389 562**
Short term liabilities			
Debt to group company	50	50	50
Accounts payable	3 538	9 449	4 678
Tax liabilities	-	-	-
Other liabilities	286	196	213
Accrued expenses and deferred income	1 762	2 375	1 983
Total short term liabilities	**5 636**	**12 071**	**6 923**
Total equity and liabilities	**366 727**	**41 274**	**396 484**

NOTES

NOTE 1 - Accounting principles

PledPharma applies International Financial Reporting Standards (IFRS) as adopted by the EU. This report is prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. The parent company's interim report is prepared in accordance with the Swedish Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities and the Swedish Annual Accounts Act. Applied accounting principles and calculation methods are the same as in the latest annual report for 2016.

NOTE 2 – Additional information

Other information in accordance with IAS 34.16A are found on pages before the income statement and statement of comprehensive income. Information on earnings, cash flow and financial position, see page 5. For events after the period, see page 1.

NOTE 3 – Financial assets and debts

Group 30 June 2017

The fair value and carrying value are shown in the table below:

	Account and loan receivables	Financial debts	Total carrying amount	Fair value
Accounts receivable	-	-	**-**	**-**
Accrued but not invoiced income	-	-	**-**	**-**
Cash	363 748	-	363 748	363 748
Total assets	**363 748**	**-**	**363 748**	**363 748**
Accounts payable	-	3 538	3 538	3 538
Other liabilities	-	-	**-**	**-**
Total debts	**-**	**3 538**	**3 538**	**3 538**

Group 31 December 2016

The fair value and carrying value are shown in the table below:

	Account and loan receivables	Financial debts	Total carrying amount	Fair value
Accounts receivable	-	-	**-**	**-**
Accrued but not invoiced income	-	-	**-**	**-**
Cash	393 998	-	393 998	393 998
Total assets	**393 998**	**-**	**393 998**	**393 998**
Accounts payable	-	4 678	4 678	4 678
Other liabilities	-	-	**-**	**-**
Total debts	**-**	**4 678**	**4 678**	**4 678**

Not 4 – Related parties transactions

No related party transactions have taken place during the period.

OTHER INFORMATION

Next reports

Interim report Jan – Sept 2017, 20 October 2017
Year-end report 2017, 22 February 2018

This report, and further information is available on the website, www.pledpharma.se

This is a translation of the Swedish interim report that has not been reviewed by the company's auditor.

For further information contact:

Nicklas Westerholm, CEO
Phone: +46 73-354 20 62
E-mail: nicklas.westerholm@pledpharma.se

Michaela Gertz, CFO
Phone: +46 70-926 17 75
E-mail: michaela.gertz@pledpharma.se

This information is such information as PledPharma AB (publ) is obliged to disclose in accordance with EU market abuse regulation and the Securities Markets Act. The information was submitted, through the above contact persons, for publication on 30 August 2017 at 8.00 am (CET)

PledPharma AB (publ)
Grev Turegatan 11c, 114 46 Stockholm
Org.nr. 556706-6724
Phone: 08-679 72 10
www.pledpharma.se

Certified Adviser

The company´s Certified Advisor is Erik Penser Bank (phone +46 8 463 80 00).

Analysts who follow PledPharma

Redeye, Klas Palin.

CERTIFICATION

This report provides a true and fair overview of the company's business activities, financial position, and results of operations, and describes significant risks and uncertainties to which the company is exposed.

Stockholm, August 30, 2017

Håkan Åström *Chairman of the board*	Gunilla Osswald *Board member*	Elisabeth Svanberg *Board member*
Sten Nilsson *Board member*	Marie Ekström Trägårdh *Board member*	Nicklas Westerholm *CEO*